Skip to main content

Table 1 Model parameters values and references: base case and sensitivity analysis

From: Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

 

Base case

Sensitivity analysis

References

Parameter

 

Lower limit

Upper limit

 

Kidney cancer incidence 40+ (per 100,000)

19.8

17.82

21.78

[22]

RCC incidence (over kidney cancer incidence)

90%

85%

95%

[24, 25]

RCC incidence at diagnosis (over RCC incidence)

20%

15%

25%

[24, 25]

RCC mortality (localized disease)

1.66%

1.49%

1.83%

[23]

Transition to advanced RCC (year 1)

13.18%

11.86%

14.49%

[20]

Transition to advanced RCC (years 2 and 3)

4.57%

4.11%

5.02%

[20]

Transition to advanced RCC (years 4 and 5)

1.92%

1.73%

2.11%

[20]

Transition to advanced RCC (year 6 and 7)

1.64%

1.48%

1.81%

[20]

Transition to advanced RCC (year 8 to 10)

1.26%

1.13%

1.38%

[20]

Advanced RCC of favorable or intermediate risk

89%

80.1%

97.9%

[26]

Transition to post-advanced RCC

100%

  

[7, 13]